Authors

Celestia S. Higano, MD, FACP

Latest:

Dr. Higano on the State of Immunotherapy in Prostate Cancer

Celestia S. Higano, MD, FACP, discusses the state of immunotherapy in prostate cancer.

Celestia S. Higano, MD, FACP, University of Wash

Celestia S. Higano, MD, FACP, University of Washi

Celestia S. Higano, MD, FACP, University of Washing

Celestia S. Higano, MD, FACP, University of Washington

Cem Akin, MD, University of Michigan

Cesar Rodriguez Valdes, MD

Latest:

Dr. Rodriguez on Evolving Role of Small Molecules in Multiple Myeloma

Cesar Rodriguez Valdes, MD, assistant professor of Hematology and Oncology, Wake Forest University Comprehensive Cancer Center, highlights the evolving role of small molecules in multiple myeloma.

Chad Cherington, MD

Latest:

Dr. Cherington on the Use of Immunotherapy and Targeted Therapy in Lung Cancer

Chad Cherington, MD, discusses the use of immunotherapy and targeted therapy in lung cancer.

Chad Pecot, MD

Latest:

Dr. Pecot on Selecting Between Available Targeted Therapies in NSCLC

Chad V. Pecot, MD, discusses selecting between available targeted therapies in RET-, KRAS-, and MET exon 14 skipping–mutant non–small cell lung cancer.

Chan Cheah, MD

Latest:

Dr. Cheah on Treatment for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Chan Cheah, MD, University of Western Australia, discusses treatment for patients with nodular lymphocyte predominant Hodgkin lymphoma.

Chandan Guha, MBBS, PhD

Latest:

To Radiation With Love: A Bench-to-Bedside Immunotherapy Story

Investigators from Montefiore developed a novel combination that has now demonstrated early-stage efficacy in metastatic lung cancer.

Chandra P. Belani, MD

Latest:

Dr. Chandra Belani on Atezolizumab in NSCLC

Chandra P. Belani, MD, deputy director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses atezolizumab in non-small cell lung cancer (NSCLC).

Chandra P. Belani, MD, Penn State Cancer Institute

Charalambos (Babis) Andreadis, MD, MSCE

Latest:

Dr. Andreadis on Antibody-Drug Conjugates in DLBCL

Charalambos (Babis) Andreadis, MD, MSCE, discusses the utility of antibody-drugs conjugates in diffuse large B-cell lymphoma.

Charles A. Henderson, MD, Peachtree Consultants

Charles A. Leath III MD

Latest:

Dr. Leath on Agents Under Investigation in Cervical Cancer

Charles A. Leath III, MD, gynecologic oncologist at the University of Alabama at Birmingham, discusses agents under investigation in cervical cancer.

Charles A. (Trey) Leath III, MD

Latest:

Dr. Leath Discusses Surgical Cytoreduction in Ovarian Cancer

Charles A. (Trey) Leath, III, MD, associate professor, UAB School of Medicine, UAB Comprehensive Cancer Center, discusses surgical cytoreduction in ovarian cancer.

Charles Bankhead

Latest:

The Landscape of Chemoprevention in Lung Cancer: A Conversation With Waun K. Hong, MD, PhD

Over the past 25 years, multiple lung cancer chemoprevention trials have missed the mark with agents that looked good on paper but lacked the molecular biology support to make a difference.

Charles Catton, MD

Latest:

Dr. Catton on Quality Assurance for Radiation Therapy for Sarcoma

Charles Catton, MD, professor, Department of Radiation Oncology University of Toronto, discusses quality assurance with radiation therapy for patients with sarcoma.

Charles Coombes, MD

Latest:

Dr. Coombes on Intriguing Results With Celecoxib in Breast Cancer

Charles Coombes, MD, professor of medical oncology, Imperial College London, discusses surprising results from a recent study examining celecoxib’s impact on breast cancer progression and relapse.